Go to Market Mercy has strengthened its go to market with the appointment of Chief Commercial Officer Darrin Crisitello in February 2026 and is preparing to commercialize its ovarian cancer test following a $59 million Series B in 2025. The company is targeting clinical labs, cancer centers, and payer organizations to scale adoption of its liquid biopsy platform.

Ovarian Test Launch In September 2025 Mercy launched a blood based ovarian cancer test, with a planned rollout in the first quarter of 2026. This creates near term sales opportunities with OB GYN clinics, screening programs, and academic medical centers, as well as reimbursement discussions with insurers.

Validation Partnerships The extracellular vesicle based liquid biopsy platform is positioned for collaborative validation with research institutions and contract labs, enabling broader clinical evidence and potential collaboration with pharma partners on companion diagnostics.

Growth Funding A $59 million Series B funding round in 2025, plus recognition like the 2024 Disruptive Technology Award, strengthens Mercy's credibility and enables expanded sales channels, partnerships, and clinical studies across oncology markets.

Market Readiness Mercy operates in a high growth cancer detection market with a focus on early screening and multicancer potential, supported by HIPAA compliant infrastructure and enterprise ready cloud tools, creating opportunities to engage health systems and payers for reimbursement ready assays.